Physician profile
Nelson Chow
NPI 1427142470
$1,767.68
in general payments reported to CMS, 2019-2025
17 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $125 · 2021: $265 · 2022: $225 · 2023: $476 · 2024: $175 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $660.26 | 2019-2022 | |
| Travere Therapeutics, INC. | $535.57 | 2023-2024 | |
| Genzyme Corporation | $135.86 | 2025 | |
| Aurinia Pharma U.S., INC. | $113.51 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Amgen INC. | $53.08 | 2024-2025 | Krystexxa, Tavneos |
| Genentech USA, INC. | $33.23 | 2019-2022 | |
| Vifor Pharma, INC. | $21.28 | 2024 | Veltassa |
| Horizon Therapeutics Plc | $20.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.15 | 2023 | Cyltezo, Jardiance |
| Lilly USA, LLC | $18.43 | 2023 | Mounjaro |
| Recordati_rare_diseases_inc. | $17.08 | 2022 | |
| Eusa Pharma (US) LLC | $17.08 | 2022 | |
| Janssen Biotech, INC. | $17.02 | 2023 | Tremfya |
| Glaxosmithkline, LLC. | $16.83 | 2023 | Benlysta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $14.83 | 2022 | |
| Novo Nordisk INC | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.